{"nctId":"NCT00829296","briefTitle":"Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries","startDateStruct":{"date":"2009-01"},"conditions":["Hypertension","Diabetes"],"count":70,"armGroups":[{"label":"nebivolol","type":"EXPERIMENTAL","interventionNames":["Drug: nebivolol"]},{"label":"Metoprolol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metoprolol"]}],"interventions":[{"name":"nebivolol","otherNames":["bystolic"]},{"name":"Metoprolol","otherNames":["lopressor"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Established Type 2 diabetic not treated with insulin\n* Stage 1 hypertensives blood pressure \\> 130/80 mmHg and \\< 160/100 mmHg\n* BMI \\< 35\n* Hemoglobin A1C \\< 8.5\n* Must be postmenopausal or taking some form of birth control of surgically sterile\n\nExclusion Criteria:\n\n* Acute myocardial infarction, unstable angina, stroke or TIA within the past year.\n* Active angina in the last three months\n* Diabetes requiring treatment with insulin\n* Severe asthma\n* Female who are pregnant, planning to be pregnant during the study period, lactating or women of childbearing potential who are not using a medically approved method of contraception\n* Recent history of substance or alcohol abuse .\n* Uncontrolled hypertension systolic blood pressure \\>160mmHg or diastolic blood pressure \\> 100 mmHg","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Central Systolic Blood Pressure (SBP)","description":"Changes in aortic impedance in patients on nebivolol vs. metoprolol succinate in Type 2 hypertensive diabetic patients as measured by the change from baseline in central systolic blood pressure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125.3","spread":"8.0"},{"groupId":"OG001","value":"127.8","spread":"8.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121.6","spread":"8.2"},{"groupId":"OG001","value":"123.8","spread":"11.1"}]}]}]},{"type":"SECONDARY","title":"Change in Pulse Wave Velocity (PWV)","description":"To examine the effect of nebivolol versus metoprolol succinate in Type 2 hypertensive diabetic patients on other measures of central conduit artery function such as pulse wave velocity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.48","spread":"0.8"},{"groupId":"OG001","value":"6.52","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"0.9"},{"groupId":"OG001","value":"6.4","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Change in Augmentation Index","description":"Augmentation index is defined as the percentage of the central pulse pressure which is attributed to the reflected pulse wave and, therefore, reflects the degree to which central arterial pressure is augmented by wave reflection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":"7.1"},{"groupId":"OG001","value":"26.2","spread":"8.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":"7.4"},{"groupId":"OG001","value":"24.6","spread":"6.7"}]}]}]},{"type":"SECONDARY","title":"Change in Pulse Pressure Amplification","description":"To examine the effect of nebivolol versus metoprolol succinate in Type 2 hypertensive diabetic patients on other measures of central conduit artery function such as pulse pressure amplification (central pulse pressure /brachial pulse pressure).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"0.08"},{"groupId":"OG001","value":"0.79","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.09"},{"groupId":"OG001","value":"0.85","spread":"0.12"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":34},"commonTop":["Fatigue","Diarrhea","Dizziness"]}}}